🔍
Search Results - camilo+rojas
5
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Small Molecule Neutral Sphingomyelinase 2 (nSMase2) Inhibitors
Unmet NeedNeutral sphingomyelinase 2 (nSMase2) is expressed in neurons and hydrolyzes sphingomyelin, producing the lipid ceramide, which functions in stress responses leading to apoptosis, cell growth arrest, and differentiation. Increased levels of ceramides have been associated with many neurological disorders, including Alzheimer’s disease, multiple...
Published: 3/14/2025
|
Inventor(s):
Takashi Tsukamoto
,
Niyada Hin
,
Ondrej Stepanek
,
Barbara Slusher
,
Camilo Rojas
,
Ajit Thomas
Keywords(s):
Antagonists/Inhibitors
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Technology Classifications > Therapeutic Modalities > Small Molecules
Inhibition of nSMase for the Treatment of Human Immunodeficiency Virus Infection
Unmet NeedHuman immunodeficiency virus (HIV) is a retrovirus that negatively impacts the immune system, leading to immunosuppression and increased susceptibility to secondary, opportunistic infections and some cancers. It is estimated that 36.7 million people worldwide are currently living with HIV. Presently, HIV has no cure and requires life-long...
Published: 3/13/2025
|
Inventor(s):
Norman Haughey
,
Barbara Slusher
,
Camilo Rojas
Keywords(s):
Antagonists/Inhibitors
,
Disease Indication
,
HIV
,
Infectious Diseases
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Clinical and Disease Specializations > Infectious Diseases > HIV
Discovery of Small Molecule Inhibitors of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative Diseases
Unmet NeedIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhibition of human nSMase2 may preserve neuronal function...
Published: 3/13/2025
|
Inventor(s):
Barbara Slusher
,
Camilo Rojas
,
Ajit Thomas
,
Radim Nencka
,
Michal Sala
,
Hubert Hrebabecky
,
Norman Haughey
Keywords(s):
Alzheimer's Disease
,
Antagonists/Inhibitors
,
Assay
,
Clinical Diagnostics
,
CNS and Neurological Disorders
,
Disease Indication
,
In Vitro Diagnostics
,
Non-novel
,
Off-the-shelf
,
Predicted Novelty
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Neurology
,
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Neurology > Alzheimer's Disease
Discovery of 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP) a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases
Unmet NeedAlzheimer’s disease (AD) is the most common form of dementia, affecting approximately 5.7 million people in the United States in 2018. Yet, no cure exists for AD, and AD therapeutics presently on the market fail to treat the disease’s underlying causes. Recent studies in mice reveal that exosomes released from glial cells contribute to the...
Published: 3/14/2025
|
Inventor(s):
Barbara Slusher
,
Camilo Rojas
,
Ajit Thomas
,
Norman Haughey
,
Marc Ferrer
,
Xin Hu
Keywords(s):
Antagonists/Inhibitors
,
Cancers
,
CNS and Neurological Disorders
,
Disease Indication
,
Novel
,
Predicted Novelty
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations > Neurology
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities > Small Molecules
Quantitation of GCPII Enzymatic Activity in Human Skin Biopsies as a Clinical Biomarker
We have identified a unique tissue preparation and enzymatic assay conditions to quatitatively monitor glutamate carboxypeptidase II (GCPII) activity in human skin biopsy samples. This assay can be utilzed as a phanacodynamic (PD) marker in the clinical development of novel GCPII inhibitors. This new assay is a significant improvement over GCPII biomarker...
Published: 3/13/2025
|
Inventor(s):
Barbara Slusher
,
Camilo Rojas
,
Marigo Stathis
,
Michael Polydefkis
Keywords(s):
Assay
,
Biomarker
,
Clinical Diagnostics
,
CNS and Neurological Disorders
,
Disease Indication
,
In Vitro Diagnostics
,
Multiple CNS Indications
,
Pharmakodynamic Biomarker
,
Therapeutic Matter
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Neurology
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Diagnostics
,
Technology Classifications > Therapeutic Modalities
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum